Conditional mutator phenotypes in hMSH2-deficient tumor cell lines

Science

Volumn 277, Issue 5331, 1997, Pages 1523-1526

  Richards, Burt ^a   Zhang, Hong ^a   Phear, Geraldine ^a   Meuth, Mark ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOSOMAL DOMINANT DISORDER; COLON CANCER; GENE MUTATION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH;

CELL COUNT; CELL DIVISION; DNA REPAIR; DNA REPLICATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; FRAMESHIFT MUTATION; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MICROSATELLITE REPEATS; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASMS; OUABAIN; OVARIAN NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 0030817162     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5331.1523     Document Type: Article

References (41)

1. A. de la Chapelle and P. Peltomäki, Annu. Rev. Genet. 29, 329 (1995); K. W. Kinzler and B. Vogelstein, Cell 87, 159 (1996).
2. A. de la Chapelle and P. Peltomäki, Annu. Rev. Genet. 29, 329 (1995); K. W. Kinzler and B. Vogelstein, Cell 87, 159 (1996).
3. N. C. Nicolaides et al., Nature 371, 75 (1994).
4. F. S. Leach et al., Cell 75, 1215 (1993).
5. D. Shibata, M. A. Peinado, Y. Ionov, S. Malkhosyan, M. Perucho, Nature Genet. 6, 273 (1994).
6. R. Parsons et al., Cell 75, 1227 (1993).
7. J. C. Boyer et al., Cancer Res. 55, 6063 (1995).
8. L. A. Loeb, ibid. 51, 3075 (1991); N. P. Bhattacharyya, A. Skandalis, A. Ganesh, J. Groden, M. Meuth, Proc. Natl. Acad. Sci. U.S.A. 91, 6319 (1994); J. R. Eshleman et al., Oncogene 10, 33 (1995); V. Lazar et al., Hum. Mol. Genet. 3, 2257 (1994); S. Markowitz et al., Science 268, 1336 (1995); N. Rampino et al., ibid. 275, 967 (1997); J. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9049 (1996).
9. L. A. Loeb, ibid. 51, 3075 (1991); N. P. Bhattacharyya, A. Skandalis, A. Ganesh, J. Groden, M. Meuth, Proc. Natl. Acad. Sci. U.S.A. 91, 6319 (1994); J. R. Eshleman et al., Oncogene 10, 33 (1995); V. Lazar et al., Hum. Mol. Genet. 3, 2257 (1994); S. Markowitz et al., Science 268, 1336 (1995); N. Rampino et al., ibid. 275, 967 (1997); J. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9049 (1996).
10. L. A. Loeb, ibid. 51, 3075 (1991); N. P. Bhattacharyya, A. Skandalis, A. Ganesh, J. Groden, M. Meuth, Proc. Natl. Acad. Sci. U.S.A. 91, 6319 (1994); J. R. Eshleman et al., Oncogene 10, 33 (1995); V. Lazar et al., Hum. Mol. Genet. 3, 2257 (1994); S. Markowitz et al., Science 268, 1336 (1995); N. Rampino et al., ibid. 275, 967 (1997); J. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9049 (1996).
11. L. A. Loeb, ibid. 51, 3075 (1991); N. P. Bhattacharyya, A. Skandalis, A. Ganesh, J. Groden, M. Meuth, Proc. Natl. Acad. Sci. U.S.A. 91, 6319 (1994); J. R. Eshleman et al., Oncogene 10, 33 (1995); V. Lazar et al., Hum. Mol. Genet. 3, 2257 (1994); S. Markowitz et al., Science 268, 1336 (1995); N. Rampino et al., ibid. 275, 967 (1997); J. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9049 (1996).
12. L. A. Loeb, ibid. 51, 3075 (1991); N. P. Bhattacharyya, A. Skandalis, A. Ganesh, J. Groden, M. Meuth, Proc. Natl. Acad. Sci. U.S.A. 91, 6319 (1994); J. R. Eshleman et al., Oncogene 10, 33 (1995); V. Lazar et al., Hum. Mol. Genet. 3, 2257 (1994); S. Markowitz et al., Science 268, 1336 (1995); N. Rampino et al., ibid. 275, 967 (1997); J. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9049 (1996).
13. L. A. Loeb, ibid. 51, 3075 (1991); N. P. Bhattacharyya, A. Skandalis, A. Ganesh, J. Groden, M. Meuth, Proc. Natl. Acad. Sci. U.S.A. 91, 6319 (1994); J. R. Eshleman et al., Oncogene 10, 33 (1995); V. Lazar et al., Hum. Mol. Genet. 3, 2257 (1994); S. Markowitz et al., Science 268, 1336 (1995); N. Rampino et al., ibid. 275, 967 (1997); J. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9049 (1996).
14. L. A. Loeb, ibid. 51, 3075 (1991); N. P. Bhattacharyya, A. Skandalis, A. Ganesh, J. Groden, M. Meuth, Proc. Natl. Acad. Sci. U.S.A. 91, 6319 (1994); J. R. Eshleman et al., Oncogene 10, 33 (1995); V. Lazar et al., Hum. Mol. Genet. 3, 2257 (1994); S. Markowitz et al., Science 268, 1336 (1995); N. Rampino et al., ibid. 275, 967 (1997); J. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9049 (1996).
15. J. T. Drummond, G.-M. Li, M. J. Longley, P. Modrich, Science 268, 1909 (1995); S. Acharya et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13629 (1996); N. Papadopoulos et al., Science 268, 1915 (1995); J. I. Risinger et al., Nature Genet. 14, 102 (1996).
16. J. T. Drummond, G.-M. Li, M. J. Longley, P. Modrich, Science 268, 1909 (1995); S. Acharya et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13629 (1996); N. Papadopoulos et al., Science 268, 1915 (1995); J. I. Risinger et al., Nature Genet. 14, 102 (1996).
17. J. T. Drummond, G.-M. Li, M. J. Longley, P. Modrich, Science 268, 1909 (1995); S. Acharya et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13629 (1996); N. Papadopoulos et al., Science 268, 1915 (1995); J. I. Risinger et al., Nature Genet. 14, 102 (1996).
18. J. T. Drummond, G.-M. Li, M. J. Longley, P. Modrich, Science 268, 1909 (1995); S. Acharya et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13629 (1996); N. Papadopoulos et al., Science 268, 1915 (1995); J. I. Risinger et al., Nature Genet. 14, 102 (1996).
19. J. I. Risinger et al., Cancer Res. 55, 5664 (1995).
20. K. Orth et al., Proc. Natl. Acad. Sci. U.S.A. 91, 9495 (1994).
21. Most of the cell lines used in these experiments were obtained from the American Type Culture Collection. MRC-5 was obtained from the Imperial Cancer Research Fund Cell Production Facility. 2774 was the kind gift of T. Kunkel. All cultures were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Mutation rates were determined by the Luria-Delbrück fluctuation test [S. E. Luria and M. Delbrück, Genetics 28, 491 (1943)]. Inocula containing 100 cells were grown for 2 weeks on 35-mm tissue culture wells. Colonies formed after this time were treated with trypsin and transferred to 100-mm dishes. After 5 days, the replica cultures were plated on 6-thioguanine (5 μg/ml) to determine mutation rate at the HPRT locus or on 1 μM ouabain to determine the rate of mutation to resistance to this drug. After 2 weeks, plates were stained and colonies larger than 50 cells were counted. The mutation rate was calculated by the method of the mean [R. L. Capizzi and J. W. Jameson, Mutat. Res. 17, 147 (1973)].
22. Most of the cell lines used in these experiments were obtained from the American Type Culture Collection. MRC-5 was obtained from the Imperial Cancer Research Fund Cell Production Facility. 2774 was the kind gift of T. Kunkel. All cultures were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Mutation rates were determined by the Luria-Delbrück fluctuation test [S. E. Luria and M. Delbrück, Genetics 28, 491 (1943)]. Inocula containing 100 cells were grown for 2 weeks on 35-mm tissue culture wells. Colonies formed after this time were treated with trypsin and transferred to 100-mm dishes. After 5 days, the replica cultures were plated on 6-thioguanine (5 μg/ml) to determine mutation rate at the HPRT locus or on 1 μM ouabain to determine the rate of mutation to resistance to this drug. After 2 weeks, plates were stained and colonies larger than 50 cells were counted. The mutation rate was calculated by the method of the mean [R. L. Capizzi and J. W. Jameson, Mutat. Res. 17, 147 (1973)].
23. B. Richards, unpublished data.
24. W. E. Glaab and K. R. Tindall, Carcinogenesis 18, 1 (1997).
25. S. Malkhosyan, A. McCarty, H. Sawai, M. Perucho, Mutat. Res. 316, 249 (1996).
26. P. Branch, R. Hampson, P. Karran, Cancer Res. 55, 2304 (1995).
27. R. S. Freedman, E. Pihl, C. Kusyk, H. S. Galleger, F. Rutledge, Cancer 42, 2352 (1978).
28. R. M. Baker et al., Cell 1, 9 (1974).
29. R was elevated 24-to 35-fold in tumor cells deficient in other mismatch repair components.
30. Analysis of HPRT mutations was performed as in (20), except that an ABI automated sequencer (Model 377) was used to determine the base alterations. Positions of mutations in the coding sequence [D. Jolly et al., Proc. Natl. Acad. Sci. U.S.A. 80, 477 (1983)] are presented with the A in the ATG initiation codon being nucleotide 1. Mutations in the introns that alter splicing are numbered with respect to the HPRT genomic sequence [A. Edwards et al., Genomics 6, 593 (1990)].
31. Analysis of HPRT mutations was performed as in (20), except that an ABI automated sequencer (Model 377) was used to determine the base alterations. Positions of mutations in the coding sequence [D. Jolly et al., Proc. Natl. Acad. Sci. U.S.A. 80, 477 (1983)] are presented with the A in the ATG initiation codon being nucleotide 1. Mutations in the introns that alter splicing are numbered with respect to the HPRT genomic sequence [A. Edwards et al., Genomics 6, 593 (1990)].
32. N. P. Bhattacharyya et al., Hum. Mol. Genet. 4, 2057 (1995).
33. Microsatellite instability was analyzed as in (20). DNA purified from cultures grown from single cells of the indicated lines was used to amplify microsatellite loci. Four loci were assayed: BAT26, which contains a mononucleotide run; D10S197 and D16S521, which are both dinucleotide repeats; and D7S1794, which contains a trinucleotide repeat. The frequency of instability presented in the text represents the fraction of subclones from each of the lines exhibiting novel alleles at the loci. Patterns of alleles at one of the microsatellite loci (D10S197) in single cell clones isolated from 2774 are presented in Fig. 1.
34. F. Palombo et al., Science 268, 1912 (1995); L. T. da Costa et al., Nature Genet. 9, 10 (1995).
35. F. Palombo et al., Science 268, 1912 (1995); L. T. da Costa et al., Nature Genet. 9, 10 (1995).
36. T. G. Graeber et al., Mol. Cell. Biol. 14, 6264 (1994).
37. T. Y. Reynolds, S. Rockwell, P. M. Glazer, Cancer Res. 56, 5754 (1996).
38. G. Marra et al., Oncogene 13, 2189 (1996); M. Meyers et al., Cancer Res. 57, 206 (1997).
39. G. Marra et al., Oncogene 13, 2189 (1996); M. Meyers et al., Cancer Res. 57, 206 (1997).
40. B. S. Strauss, Cancer Res. 52, 249 (1992).
41. We thank D. Carroll, B. Preston, and J. Roth for critically reading this manuscript. Supported by a National Cancer Institute grant (R01-CA-62244) to M.M. and an NIH training grant (T32-CA-09602) to B.R.